The U.S. Food and Drug Administration (FDA) announced on 2025-08-06 that the label for Metformin Hydrochloride now includes a Boxed Warning. This significant label revision highlights the serious risk of lactic acidosis associated with the drug, based on postmarketing cases.
Background
Metformin Hydrochloride is a widely used medication, often prescribed for managing certain conditions. The new Boxed Warning specifically addresses the risk of metformin-associated lactic acidosis. This severe adverse event has been identified through postmarketing surveillance, with reported cases resulting in serious outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning emphasizes that the onset of metformin-associated lactic acidosis is often subtle, making early detection challenging for clinicians and patients. This condition is a critical safety concern for drugs containing metformin hydrochloride, necessitating careful consideration of patient risk factors and clinical presentation.
What this means
The addition of a Boxed Warning to the Metformin Hydrochloride label serves as a crucial update for healthcare professionals and patients. It reinforces the necessity for heightened vigilance regarding the potential for lactic acidosis, a life-threatening complication. Clinicians are advised to be acutely aware of the signs and symptoms, such as hypothermia, hypotension, and resistant bradyarrhythmias, which have been observed in fatal postmarketing cases. This label change aims to improve patient safety by ensuring that the serious risks associated with metformin-associated lactic acidosis are clearly communicated and understood across the medical community, guiding appropriate monitoring and management strategies.
Source
This information regarding the label revision for Metformin Hydrochloride was provided by the FDA on 2025-08-06. The details of the Boxed Warning are available on the DailyMed website, hosted by dailymed.nlm.nih.gov.